ANF-Rho in the Treatment of Chronic Neutropenia

Status:
Withdrawn

Trial end date:
2016-10-01

Target enrollment:

Participant gender:

A 6 month safety, tolerability, efficacy and pharmacokinetic study with ANF-Rho to treat patients with chronic neutropenia.

Phase 1/Phase 2

Prolong Pharmaceuticals